The System Biology Group, Inc., is dedicated at present to accelerating the global adoption of a comprehensive series of behavioral methods aimed at preventing or reversing serious diseases of aging.
Relevant conditions include diabetes type 2 and other metabolic disorders; major bone and joint ailments; most forms of cancer in all stages — initiation, progression, and metastasis; atherosclerosis, stroke, and other cardiovascular disorders; Alzheimer’s disease, Parkinson’s, multiple sclerosis, and other neurodegenerative disorders; ulcerative colitis and Crohn’s disease; and dozens of other conditions, including many conditions once viewed as purely psychological in nature.
Recent work also suggestively linked the generalized inflammatory model of chronic disease pioneered by the Group to the etiology of childhood diseases with strong inflammatory components, including diabetes type 1, asthma and other dangerous allergic conditions, and many childhood cancers. Apparent causal mechanisms in this case include a mixture of multi-generational and parental epigenetic modes of transmission as well as early-childhood environmental influences.
As part of its work in translational medicine, the Group is currently intent on making widely available inexpensive home tests it has developed of key markers of low-grade chronic inflammation. Recent research — including nine years of longitudinal studies by Group researchers of subjects from their 20s to late 90s in the Stanford Aging Cohort (2007-16) — suggests that persistent low-grade inflammation over time is among the most reliable markers of general health and risks for all-cause mortality.
In the short term, this part of the Systems Biology Group’s work is focused on bringing to market a series of inexpensive technologies we have developed for tracking the rise and fall of those markers over time (the InflammaTestTM* system).
In our future pipeline: development of a real-time (RT) medical device worn by the user (RT InflammaTestTM*), capable of detecting and analyzing key circulating inflammatory markers using advanced nano-sensor technologies.
Real-time analysis of these markers will allow inexpensive tracking over long periods of what are currently the strongest known measures of human lifespan and healthspan.
Aging and Chronic Disease
“As of 2012, there were approximately 810 million persons age 60 years or older worldwide and the number is projected to grow to more than 2 billion by 2050.” (United Nations Population Fund)
“200 millions of humans with chronic diseases of aging by the year 2030″ (World Health Organization | Global Status Report 2014)
The number of older adults is growing at an unprecedented rate. The public health consequences of this population growth on a global scale are obvious, and include predicted sharp rises in the most devastating diseases of aging on a global scale.
Research by our Group and others suggest that by systematic application of a comprehensive series of behavioral therapies low-grade chronic inflammation can be controlled without “magic bullet” pharmaceutical interventions, and that major age-related damage can be delayed or even reversed.
Researchers in the Group track developments in every medical and research field involved in immunological and aging research. They make use of high-throughput technologies in systems biology in blood monitoring and data analytics to construct models of how aging affects, and is affected by, low-grade chronic inflammation.
Our research mission is to translate this information into systematically constructed protocols designed to combat low-grade chronic inflammation, decreasing disease risk and ameliorating clinical symptoms.
Tracking Low-Grade Inflammation Over Time
Behavioral medicine protocols can be guided and fine-tuned by regular monitoring of circulating inflammatory markers. The aim of such monitoring is to enable a kind of personalized behavioral medicine guided by those tests. The aim of this approach to medicine is to overcome sharp theoretical limits, due to a wide range of indeterminate processes in molecular biology, that impose sharp limits on the effectiveness of pharmaceutical approaches to so-called precision medicine. These limits are discussed at length in a paper-in-progress authored by the Group.
*InflammaTestTM is a trademark of the Systems Biology Group, Inc.